We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up
Read MoreHide Full Article
Arena Pharmaceuticals, Inc. reported earnings of 16 cents per share in the fourth quarter of 2016, as against the year-ago loss of 13 cents and the Zacks Consensus Estimate of a loss of 9 cents. Higher revenues and lower costs boosted earnings in the quarter.
Arena’s shares has traded above the Zacks classified Medical-Biomed/Genetics industry so far this year. Its shares gained 19.7%, while the industry registered an increase of 10.2%.
Total revenue in the quarter was $85.4 million, much higher than the year-ago figure of $7.8 million. Revenues included $15.2 million in net product sales of Belviq, $1.3 million in milestone payments from Eisai and Ildong for Belviq and $66.1 million in the form of upfront Belviq payments.
Belviq is, the only approved product in Arena’s portfolio which was launched in Sep 2016 approved for chronic weight management in adult patients.
Quarter in Detail
During the fourth quarter of 2016, Belviq generated sales of $15.2 million, compared with $3.9 million a year ago.
Research & development (R&D) expenses declined 41% year over year to $11.9 million. Likewise, general & administrative (G&A) expenses were $7.3 million, down 24.7% year over year.
Pipeline Update
Arena’s pipeline consists of several early- to mid-stage candidates targeting different therapeutic areas. These include ralinepag (pulmonary arterial hypertension), etrasimod (a number of autoimmune diseases) and APD371 (pain and fibrotic diseases). Phase II trials on etrasimod and ralinepag are ongoing. The comapny expects to report data on etrasimod for ulcerative colitis by 2017-end and on ralinepag for pulmonary arterial hypertension by mid-2017. Meanwhile, the company initiated a phase II trial on APD371 for the treatment of pain linked with Crohn's disease during the quarter.
2016 Results
Full-year sales totaled $124 million, compared with $38.3 million a year ago. Sales beat the Zacks Consensus Estimate of $48 million by a solid margin.
Full-year loss of 9 cents per share was significantly narrower than Zacks Consensus Estimate of a loss of 34 cents. The company had posted a loss of 45 cents a year ago.
2017 Guidance
The company expects net cash used in operating and investing activities in the range of $80 million to $100 million for 2017.
Arena Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Addus HomeCare’s earnings estimates increased from $1.38 to $1.41 for 2017 over the last 30 days. The company posted positive earnings surprises in two of the four trailing quarters, with an average beat of 10.10%.
The Advisory Board’s earnings estimates increased from $1.41 to $1.48 for 2017 over the last 30 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 33.41%.
BioCryst Pharma’s loss per share estimates narrowed from 88 cents to 66 cents for 2017 and from a loss of 93 cents to 70 cents over the last 30 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 20%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up
Arena Pharmaceuticals, Inc. reported earnings of 16 cents per share in the fourth quarter of 2016, as against the year-ago loss of 13 cents and the Zacks Consensus Estimate of a loss of 9 cents. Higher revenues and lower costs boosted earnings in the quarter.
Arena’s shares has traded above the Zacks classified Medical-Biomed/Genetics industry so far this year. Its shares gained 19.7%, while the industry registered an increase of 10.2%.
Total revenue in the quarter was $85.4 million, much higher than the year-ago figure of $7.8 million. Revenues included $15.2 million in net product sales of Belviq, $1.3 million in milestone payments from Eisai and Ildong for Belviq and $66.1 million in the form of upfront Belviq payments.
Belviq is, the only approved product in Arena’s portfolio which was launched in Sep 2016 approved for chronic weight management in adult patients.
Quarter in Detail
During the fourth quarter of 2016, Belviq generated sales of $15.2 million, compared with $3.9 million a year ago.
Research & development (R&D) expenses declined 41% year over year to $11.9 million. Likewise, general & administrative (G&A) expenses were $7.3 million, down 24.7% year over year.
Pipeline Update
Arena’s pipeline consists of several early- to mid-stage candidates targeting different therapeutic areas. These include ralinepag (pulmonary arterial hypertension), etrasimod (a number of autoimmune diseases) and APD371 (pain and fibrotic diseases). Phase II trials on etrasimod and ralinepag are ongoing. The comapny expects to report data on etrasimod for ulcerative colitis by 2017-end and on ralinepag for pulmonary arterial hypertension by mid-2017. Meanwhile, the company initiated a phase II trial on APD371 for the treatment of pain linked with Crohn's disease during the quarter.
2016 Results
Full-year sales totaled $124 million, compared with $38.3 million a year ago. Sales beat the Zacks Consensus Estimate of $48 million by a solid margin.
Full-year loss of 9 cents per share was significantly narrower than Zacks Consensus Estimate of a loss of 34 cents. The company had posted a loss of 45 cents a year ago.
2017 Guidance
The company expects net cash used in operating and investing activities in the range of $80 million to $100 million for 2017.
Arena Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Arena Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Arena Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Arena currently carries a Zacks Rank #4 (Sell). Better-ranked stocks in the health care sector include Addus HomeCare Corporation (ADUS - Free Report) , The Advisory Board Company and BioCryst Pharmaceuticals, Inc. (BCRX - Free Report) . Each of these stocks carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Addus HomeCare’s earnings estimates increased from $1.38 to $1.41 for 2017 over the last 30 days. The company posted positive earnings surprises in two of the four trailing quarters, with an average beat of 10.10%.
The Advisory Board’s earnings estimates increased from $1.41 to $1.48 for 2017 over the last 30 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 33.41%.
BioCryst Pharma’s loss per share estimates narrowed from 88 cents to 66 cents for 2017 and from a loss of 93 cents to 70 cents over the last 30 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 20%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>